



PRESS RELEASE

October 4, 2019
Fuji Pharma Co., Ltd.

Notice of Change of Representative Director (Change of President)

Fuji Pharma Co., Ltd. (hereinafter “Fuji Pharma”) announced that it has approved a resolution passed at the Board of Directors’ meeting held on October 4, 2019, as follows.

1. Reason for the change

Our company has developed a long-term vision, in order to respond to major changes in the business environment and initiatives for the future. In order to maintain speed, and maximize the corporate value by establishing a new management structure for a strong management foundation, President & CEO, Eiji Takemasa has proposed to resign from the position as Representative Director and President & CEO, and the Board of Directors’ meeting was held on October 4, 2019, and resolved the change of Representative Director.

2. Details of the change

Name	New Position (After closure of Board of Directors’ meeting on October 4, 2019)	Current Position (Before closure of Board of Directors’ meeting on October 4, 2019)
Eiji Takemasa (Resigning)	Director	Representative Director, President & CEO

- After the resignation, Eiji Takemasa continues to fulfill the responsibility as a Director until the expiry of his term (at the closure of the Shareholders meeting scheduled on December 19, 2019).
- After closure of the Board of Directors’ meeting, Hirofumi Imai (Chairman & Representative Director) will be the only Representative Director

3. Newly appointed President & CEO

Name	New Position (After closure of Board of Directors’ meeting on October 4, 2019)	Current Position (Before closure of Board of Directors’ meeting on October 4, 2019)
Takayuki Iwai (Newly Appointed)	President & CEO and General Manager of Research & Development Division	Vice President & COO and General Manager of Research & Development Division

- The newly appointed President & CEO, Takayuki Iwai will be nominated as a candidate for Director in the Shareholders meeting scheduled on December 19, 2019. At the Board of Meeting on the same day, he is expected to be appointed as Representative Director and President & CEO.

4. Career summary of the new President & CEO

Name (Date of Birth)	Career summary		Number of Shares held
Takayuki Iwai (February 24, 1964)	Apr. 1986	Joined Mitsui & Co., Ltd.	4,000
	Jun. 1991	Mitsui & Co., Italy	
	Jun. 1995	Mitsui & Co., Ltd., Life Science Headquarters, Pharma Medical Division	
	Feb. 2003	Mitsui & Co., Germany	
	Dec. 2006	Fuji Pharma Director, Corporate Planning Manager (secondment)	
	Jul. 2008	Mitsui & Co., Ltd. Agriscience Service Headquarters, European Business Division General Manager	
	Jul. 2011	Mitsui & Co., Ltd. Healthcare Service Headquarters, Pharma Division General Manager	
	Jul. 2017	Mitsui & Co., U.S.A, SVP and American Headquarters Healthcare Service Product Division Chief	
	Oct. 2019	Joined Fuji Pharma as Vice President & COO, and Chief Executive for Research & Development Division	
Oct. 2019	President & CEO, and Chief Executive for Research & Development Division (current position)		